antineoplaston A10

Antineoplaston A10 is a small molecule investigational drug originally isolated from human urine and now produced synthetically. It belongs to the class of n-acyl-alpha amino acids and derivatives. The active component is 3-phenylacetylamino-2,6-piperidinedione. Antineoplaston A10 has been studied primarily as an experimental cancer therapy for various malignancies including glioma (notably diffuse intrinsic brain stem glioma), sarcoma, lymphoma, lung cancer, liver cancer, kidney cancer and others. Its proposed mechanisms include intercalation into DNA leading to cell cycle arrest in G1 phase with reduced mitosis and protein synthesis; inhibition of ras-oncogene expression; activation of tumor suppressor gene p53 resulting in cell differentiation and apoptosis[1][5][8]. It has also been described as an apoptosis stimulant and cell cycle inhibitor[4]. Clinical trials have explored both intravenous and oral administration routes.

Brand names

Atengenal

Other names

N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamidebenzeneacetamide N-(2,6-dioxo-3-piperidinyl)-(S)Cengenal